Skip to main content

Table 1 Patient clinical characteristics

From: Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia

Patient

Age (years)

Sex

Disease status

#1

12

Male

ALL newly diagnosed

#2

3

Female

ALL newly diagnosed

#3

2

Male

ALL newly diagnosed

#4

7

Female

ALL newly diagnosed

#5

9

Female

ALL newly diagnosed

#6

7

Female

ALL newly diagnosed

#7

7

Female

ALL newly diagnosed

#8

8

Male

ALL newly diagnosed

#9

15

Male

ALL relapse

#10

13

Female

ALL relapse

NC1

14

Female

Normal control

NC2

15

Male

Normal control

NC3

7

Male

Normal control

  1. ALL acute lymphoblastic leukemia, NC normal control